Rationally-designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 31-34

  Somu, Ravindranadh V ^a   Boshoff, Helena ^b   Qiao, Chunhua ^a   Bennett, Eric M ^a   Barry III, Clifton E ^b   Aldrich, Courtney C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MYCOBACTIN; PROTEIN MBTA; SALICYLIC ACID; SIDEROPHORE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; DRUG DESIGN; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; NUCLEOSIDES; SIDEROPHORES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444445995     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051060o     Document Type: Article

References (27)

1. World Health Organization. Tuberculosis handbook; WHO: Geneva, 1998 (WHO/TB/98.253).
2. Ratledge, C.; Dover: L. G. Iron metabolism in pathogenic bacteria. Anna. Rev. Microbial. 2000, 54, 881-941.
3. Crosa, J. H.; Walsh, C. T. Genetics and assembly line enzymology of siderophore biosynthesis in bacteria. Microbiol. Mol. Biol. Rev. 2002, 66, 223-249.
4. Vergne, A. F.; Walz, A. J.; Miller, M. J. Iron chelators from mycobacteria (1954-1999) and potential therapeutic applications. Nat. Prod. Rep. 2000, 17, 99-116.
5. Luo, M.; Fadeev, E. A.; Groves, J. T. Mycobactin-mediated iron acquisition within macrophages. Nature Chem. Biol. 2005, 1, 149-153.
6. De Voss, J. J.; Rutter, K.; Schroeder, B. G.; Su, H.; Zhu, Y.; Barry, C. E. 3rd The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1252-1257.
7. Wagner, D.; Maser, J.; Lai, B.; Cai, Z.; Barry, C. E. 3rd; zu Bentrup, K. H.; Russell, D. G.; Bermudez, L. E. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J. Immunol. 2005, 174, 1491-1500.
8. Quadri, L. E. N.; Sello, J.; Keating, T. A.; Weinreb, P. H.; Walsh, C. T. Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chem. Biol. 1998, 5, 631-645.
9. Finking, R.; Neumüller, A.; Solsbacher, J.; Konz, D.; Kretzschmar, G.; Schweitzer, M.; Krumm, T.; Marahiel, M. A. Aminoacyl adenylate substrate analogues for the inhibition of adenylation domains of nonribosomal peptide synthetases. Chembiochem 2003, 4, 903-906.
10. May, J. M.; Finking, R.; Wiegeshoff, F.; Weber, T. T.; Bandur, N.; Koert, U.; Marahiel, M. A. Inhibition of the D-alanine: D-alanyl carrier protein ligase from Bacillus subtilis increases the bacterium's susceptibility to antibiotics that target the cell wall. FEBS J. 2005, 272, 2993-3003.
11. May, J. J.; Kessler, N.; Marahiel, M. A.; Stubbs, M. T. Crystal structure of DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide synthetases. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12120-12125.
12. Gulick, A. M.; Lu, X.; Dunaway-Mariano, D. Crystal structure of 4-chlorobenzoate: CoA ligase/synthetase in the unliganded and aryl substrate-bound states. Biochemistry 2004, 43, 8670-8679.
13. Sieber, S. A.; Marahiel, M. A. Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. Chem. Rev. 2005, 105, 715-738.
14. Kim, S.; Lee, S. W.; Choi, E.-C.; Choi, S. Y. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl. Microbiol. Biotechnol. 2003, 61, 278-288.
15. Schimmel, P.; Tao, J.; Hill, J. Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J. 1998, 12, 1599-1609.
16. Copeland, R. A. In Evaluation of Enzyme Inhibitors in Drug Discovery; Wiley: Hoboken, NJ, 2005; pp 202-203.
17. Ferreras, J. A.; Ryu, J.-S.; Lello, F. D.; Tan, D. S.; Quadri, L. E. N. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersenia pestis. Nature Chem. Biol. 2005, 1, 29-32.
18. Isono, K.; Uramoto, M.; Kusakabe, H.; Miyata, N.; Koyama, H.; Ubukata, M.; Sethi, S. K.; McCloskey, J. A. Ascamycin and dealanylascamycin, nucleoside antibiotics from Streptomyces sp.. J. Antibiot. (Tokyo) 1984, 37, 670-672.
19. Castro-Pichel, J.; Garcia-Lopez, M. T.; De las Heras, F. G. A facile synthesis of ascamycin and related analogs. Tetrahedron 1987, 43, 383-389.
20. a module of Jaguar. See Supporting Information for details.
21. Backes, B. J.; Ellman, J. A. Carbon-carbon bond-forming methods on solid support. Utilization of Kenner's 'safety-catch' linker. J. Am. Chem. Soc. 1994, 116, 11171-11 172.
22. Shuman, D. A.; Robins, R. K.; Robbins, M. J. The synthesis of adenine 5′-O-sulfamoyl nucleosides related to nucleocidin. J. Am. Chem. Soc. 1969, 91, 3391-3392.
23. Peterson, E. M.; Brownell, J.; Vince, R. Synthesis and biological evaluation of 5′-sulfamoylated purinyl carbocyclic nucleosides. J. Med. Chem. 1992, 35, 3991-4000.
24. Göring, G.; Cramer, F. Synthese von Inhibitoren für die Phenylalanyl-tRNA-Synthetase: Methylen-Analoge des Phenylalanyl-adenylats. Chem. Ber. 1973, 106, 2460-2467.
25. Feldman, A. K.; Colasson, B.; Fokin, V. V. One-pot synthesis of 1,4-disubstituted 1,2,3-triazoles from in situ generated azides. Org. Lett. 2004, 6, 3897-3899.
26. Domenech, P.; Reed, M. B.; Barry, C. E. 3rd Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 2005, 73, 3492-3501.
27. See Supporting information.